Answers are grounded in this paper and cite their sources.
Review highlights advances in betasitosterol-based liposomes and polymeric scaffolds, suggesting improved stability and controlled release for drug delivery.
The combination of liposomes and betasitosterol (BS) may alter the current state of drug delivery technology. Although, liposomes are widely considered as a promising model for drug delivery of bioactive compounds, there are still significant barriers to widespread drug use. Two ways to overcome the factors associated with the effectiveness of liposomes in drug delivery are suggested. The primary involves the preparation of the liposome containing active components, while the second involves the synthesis of liposomes pre-loaded with drugs. This seeks to provide intelligent solutions to the limitations of normal liposomes such as short half-life of plasma, toxicity, stability, and poor control of long-term drug release. This review describes significant developments in integrated technologies combining the concepts of depot polymeric scaffolds with liposome technologies to bypass the limits of standard pharmaceutical liposomes.
No takes yet. Share an insight, caveat, or question.
Tiwari et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: